Blastocin

Country of origin: India

Pharm-Group: Antitumor antibiotics

Manufacturers: Menon Pharma (India)

International name: Doxorubicin

Synonyms: Adriamycin, Adriblastin, Adriblastin instant, Doxolem, Doxorubicin, Doxorubicin-Lance, Doxorubicin-Teva, Doxorubicin-Ferein, Doxorubicin-Ebeve, Doxorubicin hydrochloride, Kelix, Rastocin

Dosage forms: lyophilized powder for the preparation of injection solution 10 mg

Composition: Active ingredient - doxorubicin.

Indications for use: Acute lymphoblastic and myeloblastic leukemia; malignant lymphoma of Hodgkin and non-Hodgkin type; cancer of the breast, lung (especially small cell), bladder, thyroid, ovarian; osteogenic sarcoma; soft tissue sarcoma; Ewing's sarcoma; neuroblastoma; Wilms tumor.

Contraindications: Hypersensitivity to hydroxybenzoates, severe suppression of bone marrow function due to taking other chemotherapeutic drugs or radiation therapy, previous treatment with anthracyclines in maximum total doses, leukopenia, thrombocytopenia, anemia, severe impairment of liver and kidney function, acute hepatitis, bilirubinemia, severe heart disease (myocarditis, severe rhythm disturbances, acute phase of myocardial infarction), gastric and duodenal ulcers, bleeding, tuberculosis, cystitis (intravesical administration), pregnancy, breastfeeding. Restrictions on use: Age under 2 years and after 70 years (possible increase in the frequency of cardiotoxic effects), organic heart damage (risk of developing cardiotoxic effects at low doses).

Side effect:

1. From the cardiovascular system and blood (hematopoiesis, hemostasis): congestive heart failure, manifested by shortness of breath, swelling of the feet and ankles, rapid or irregular heartbeat and requiring immediate cessation of treatment, because the development of irreversible and ultimately fatal cardiomyopathy is possible (depending on the dose or duration of treatment, it may develop several weeks after discontinuation of the drug); acute atrial and ventricular arrhythmia (mainly in the first hours after administration); rarely, within a few days or weeks after administration - toxic myocarditis or pericarditis-myocarditis syndrome (tachycardia, heart failure, pericarditis); thrombocytopenia, leukopenia, reaching a peak 10-15 days after the start of treatment (the blood picture is usually restored on the 21st day after cessation of administration); phlebosclerosis (when administered into small veins or repeated injection into the same vein), flushing of the face and hyperemia along the vein (if administered too quickly).

2. From the gastrointestinal tract: nausea, vomiting, stomatitis or esophagitis (may occur after 5-10 days, especially when administered for three consecutive days, and lead to the development of severe infections), ulceration in the gastrointestinal tract; rarely - anorexia, diarrhea.

3. From the genitourinary system: hyperuricemia, nephropathy (associated with increased formation of uric acid), reddish color of urine (disappears within 48 hours). With intravesical administration - burning in the bladder and urethra, urination disorder (pain, difficulty, etc.), hematuria.

4. From the skin: alopecia (complete and reversible), darkening of the soles, palms and nails, recurrence of radiation erythema.

5. Allergic reactions: skin rash, itching, fever, chills, anaphylaxis.

6. Other: extravasation, cellulite, necrosis (if it gets into surrounding tissues), rarely - conjunctivitis, lacrimation.

Interaction:

Pharmaceutically incompatible with solutions of heparin, dexamethasone, fluorouracil, hydrocortisone sodium succinate, aminophylline, cephalothin (who